219 related articles for article (PubMed ID: 24473978)
1. Case of primary diffuse leptomeningeal gliomatosis.
Yamasaki K; Yokogami K; Ohta H; Yamashita S; Uehara H; Sato Y; Takeshima H
Brain Tumor Pathol; 2014 Jul; 31(3):177-81. PubMed ID: 24473978
[TBL] [Abstract][Full Text] [Related]
2. Primary diffuse leptomeningeal gliomatosis in children: a clinical pathologic correlation.
Bernardini FP; Croxatto JO; Nozza P; Rossi A; Capris P
Ophthalmic Plast Reconstr Surg; 2013; 29(2):93-7. PubMed ID: 23247038
[TBL] [Abstract][Full Text] [Related]
3. Primary diffuse leptomeningeal gliomatosis.
Jicha GA; Glantz J; Clarke MJ; Lehwald LM; Russo DP; Giannini C; Wald JT; Uhm J; Kumar N; Aksamit AJ; Wetmore CJ
Eur Neurol; 2009; 62(1):16-22. PubMed ID: 19407451
[TBL] [Abstract][Full Text] [Related]
4. A case of primary diffuse leptomeningeal gliomatosis predominantly involving the cervical spinal cord and mimicking chronic meningitis.
Heijink DS; Urgun K; Sav A; Seker A; Konya D
Turk Neurosurg; 2012; 22(1):90-4. PubMed ID: 22274977
[TBL] [Abstract][Full Text] [Related]
5. Primary diffuse leptomeningeal gliomatosis mimicking a chronic inflammatory meningitis.
Ko MW; Turkeltaub PE; Lee EB; Gonatas NK; Volpe NJ; Moster ML; Galetta SL
J Neurol Sci; 2009 Mar; 278(1-2):127-31. PubMed ID: 19135216
[TBL] [Abstract][Full Text] [Related]
6. Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review.
Hansen N; Wittig A; Hense J; Kastrup O; Gizewski ER; Van de Nes JA
Eur J Med Res; 2011 Sep; 16(9):415-9. PubMed ID: 22024443
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of MGMT gene promoter in meningiomas.
de Robles P; McIntyre J; Kalra S; Roldán G; Cairncross G; Forsyth P; Magliocco T; Hamilton M; Easaw J
Cancer Genet Cytogenet; 2008 Nov; 187(1):25-7. PubMed ID: 18992637
[TBL] [Abstract][Full Text] [Related]
8. Primary diffuse leptomeningeal gliomatosis mimicking meningeal tuberculosis.
Ruiz-Ares G; Collantes-Bellido E; Rodriguez de Rivera F; Medina-Báez J; Palomo-Ferrer F; Morales-Bastos C; Arpa J
Neurologist; 2011 May; 17(3):160-3. PubMed ID: 21532387
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
10. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
11. MGMT methylation in glioblastoma: tale of the tail.
Shah N; Schroeder B; Cobbs C
Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
[No Abstract] [Full Text] [Related]
12. Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy.
Terasaki M; Bouffet E; Maeda M; Sugita Y; Sawamura Y; Morioka M
Neurologist; 2012 Jan; 18(1):32-5. PubMed ID: 22217612
[TBL] [Abstract][Full Text] [Related]
13. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
14. Primary diffuse leptomeningeal gliomatosis: early diagnostic signs.
Sulentic V; Hajnsek S; Petelin Gadze Z; Bujan Kovac A; Nankovic S
Neurol Sci; 2015 Sep; 36(9):1697-9. PubMed ID: 25904056
[No Abstract] [Full Text] [Related]
15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
16. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
17. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
18. Primary diffuse leptomeningeal gliomatosis: an autopsy case and review of the literature.
Somja J; Boly M; Sadzot B; Moonen G; Deprez M
Acta Neurol Belg; 2010 Dec; 110(4):325-33. PubMed ID: 21305863
[TBL] [Abstract][Full Text] [Related]
19. Primary diffuse leptomeningeal gliosarcomatosis.
Watanabe Y; Hotta T; Yoshioka H; Itou Y; Taniyama K; Sugiyama K
J Neurooncol; 2008 Jan; 86(2):207-10. PubMed ID: 17628746
[TBL] [Abstract][Full Text] [Related]
20. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
